Medrx Co

Medrx Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Medrx Co (4586.T) as of Nov 19, 2026 is 103.57 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 99.57 % — a change of 4.02% (higher).

FCF Conversion

103.57 %

YoY

4.02%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Medrx Co is 2025 103.57 % . FCF Conversion Rate (FCF/EBITDA) of Medrx Co was 2024 99.57 % . It decreases by 4.02% higher compared to the previous year.

The Medrx Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
102.81 JPY
Jan 1, 2019
111.33 JPY
Jan 1, 2020
91.94 JPY
Jan 1, 2021
87.39 JPY
Jan 1, 2022
96.77 JPY
Jan 1, 2023
97.95 JPY
Jan 1, 2024
99.57 JPY
Jan 1, 2025
103.57 JPY
The Medrx Co FCF Conversion history
YEARFCF ConversionYoY
103.57 %+4.02%
99.57 %+1.65%
97.95 %+1.22%
96.77 %+10.73%
87.39 %-4.94%
91.94 %-17.42%
111.33 %+8.29%
102.81 %+0.49%
102.31 %+5.42%
97.05 %+2.97%
94.24 %-8.07%
102.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

FCF Conversion Rate (FCF/EBITDA) of Medrx Co is 103.57 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Medrx Co changed from 99.57 % to 103.57 %, representing a 4.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medrx Co

All Key Metrics — Medrx Co